<DOC>
	<DOCNO>NCT00377104</DOCNO>
	<brief_summary>This phase I trial study side effect best dose flavopiridol treat patient B-cell chronic lymphocytic leukemia small lymphocytic lymphoma . Drugs use chemotherapy , alvocidib , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Alvocidib Treating Patients With B-Cell Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxicity profile , dose-limiting toxicity , maximum tolerate dose flavopiridol ( alvocidib ) consolidation chemotherapy cytoreduction chemotherapy patient B-cell chronic lymphocytic leukemia small lymphocytic lymphoma . SECONDARY OBJECTIVES : I . Determine pharmacokinetics cellular pharmacodynamics flavopiridol patient . II . Determine complete response ( CR ) overall response rate ( CR partial response ) patient treat flavopiridol . OUTLINE : This dose-escalation study . Patients receive alvocidib intravenously ( IV ) 30 minute ( load dose ) , follow alvocidib IV 4 hour day 1 , 8 , 15 . Treatment repeat every 5 week 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos flavopiridol maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 12 patient treat MTD ( i.e. , recommend phase II dose ) . Patients undergo blood collection baseline periodically study pharmacokinetic cytokine study ( level tumor necrosis factor-alpha , interleukin [ IL ] -6 , -11 , -16 ) enzyme-linked immunosorbent assay ( ELISA ) . Interphase cytogenetics , p53 mutational status , p53/ATM function , V_H mutational status , zeta-chain-associated protein kinase 70 ( ZAP-70 ) overexpression , single nucleotide polymorphism also examine . After completion study treatment , patient follow 2 month every 3 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Diagnosis 1 follow : Bcell chronic lymphocytic leukemia ( CLL ) Small lymphocytic lymphoma ( SLL ) Must receive 13 prior therapy CLL Completed therapy 212 month ago Prior therapy must lead partial response great No evidence progressive disease ECOG performance status 02 Absolute neutrophil count ≥ 1,000/mm³ WBC ≤ 5,000/mm³ Platelet count ≥ 50,000/mm³ Cytopenia allow Creatinine &lt; 2.0 mg/dL Bilirubin ≤ 1.5 time normal ( unless due Gilbert 's disease hemolysis ) AST ≤ 2 time normal ( unless due hemolysis ) No secondary malignancy disease would limit survival &lt; 2 year No history inflammatory bowel disease unless inactive &gt; 2 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception See Disease Characteristics No concurrent chemotherapy No concurrent radiotherapy No concurrent dexamethasone corticosteroidbased antiemetic No concurrent chronic corticosteroid therapy No concurrent hormonal therapy except follow : Steroids new adrenal failure Hormones nondiseaserelated condition ( e.g. , insulin diabetes )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>